🔎 Trials Near Me

Home › Lymphoma › Oregon

Lymphoma clinical trials in Oregon

8 studies for Lymphoma are looking for participants at sites in Oregon.

Cities in Oregon

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Oregon Health and Science University, Portland
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

  • Oregon Health & Science University, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT07192471

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Oregon Health & Science University, Portland
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579

DALY II USA/ MB-CART2019.1 for DLBCL

  • Oregon Health and Science University Knight Cancer Institute, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Providence Neurological Specialties West, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Oregon Health Sciences University, Portland
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.